Cantor Fitzgerald L. P. Takes Position in DiaMedica Therapeutics, Inc. $DMAC

Cantor Fitzgerald L. P. bought a new position in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) during the third quarter, according to its most recent filing with the SEC. The firm bought 100,000 shares of the company’s stock, valued at approximately $687,000. Cantor Fitzgerald L. P. owned approximately 0.19% of DiaMedica Therapeutics as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Russell Investments Group Ltd. acquired a new position in DiaMedica Therapeutics during the third quarter worth $27,000. Police & Firemen s Retirement System of New Jersey bought a new position in DiaMedica Therapeutics in the 2nd quarter valued at about $29,000. Bank of America Corp DE lifted its position in DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after acquiring an additional 8,274 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in DiaMedica Therapeutics during the 2nd quarter valued at about $49,000. Finally, Invesco Ltd. acquired a new position in DiaMedica Therapeutics during the 2nd quarter valued at about $54,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Lake Street Capital reiterated a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, DiaMedica Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Stock Performance

NASDAQ:DMAC opened at $7.28 on Monday. The firm has a market cap of $379.14 million, a price-to-earnings ratio of -10.25 and a beta of 1.09. DiaMedica Therapeutics, Inc. has a 52 week low of $3.19 and a 52 week high of $10.42. The firm has a 50-day moving average price of $8.16 and a two-hundred day moving average price of $7.60.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.